ArticleKidney international reports2026
Time-Updated Hematuria and Kidney Disease Progression in IgAN.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systematic Review of Persistent Microscopic Hematuria and Kidney Outcomes in IgAN.Kidney international reports · 2026Article
- Hematuria in IgAN: Marker, Mediator, or Both?Kidney international reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hematuria is a hallmark feature of IgA nephropathy (IgAN); however, its long-term impact on kidney outcomes remains incompletely characterized because of time-dependent confounding and lack of a standardized cutoff. This study evaluated the longitudinal association between hematuria and kidney disease progression. Methods: We included 1771 participants with biopsy-proven IgAN. Hematuria was categorized into the following 4 groups: < 10, 10 to < 20, 20 to < 100, and ≥ 100 red blood cells (RBC)/μl. The primary outcome was a composite kidney outcome (40% estimated glomerular filtration rate [eGFR] decline or kidney failure). Conventional Cox proportional hazards models were used to assess baseline hematuria, whereas marginal structural models (MSMs) were employed to evaluate time-updated hematuria, accounting for time-dependent confounders and fluctuations in clinical parameters. Results: During a median follow-up of 48 months, the primary outcome occurred in 487 (27.5%) participants. In the fully adjusted baseline Cox model, baseline hematuria was not significantly associated with the primary outcome. In contrast, MSMs revealed that time-updated hematuria ≥ 100 RBC/μl was significantly associated with an increased risk of progression (hazard ratio [HR]: 1.53; 95% confidence interval [CI]: 1.14-2.06). The adverse impact was particularly pronounced in subgroups with a baseline eGFR < 60 ml/min per 1.73 m Conclusion: Our findings suggest that persistent hematuria ≥ 100 RBC/μl may serve as a valuable risk stratification standard, particularly given the significantly magnified risk in patients with pre-existing renal impairment or uncontrolled proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.